Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance.

Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance.

<h4>Background</h4>Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approved versions of the HIV-1 Limiting Antigen Avidity EIA (LAg) for detecting 'recent' HIV infection in cross-sectional incidence estimation. This study assesses and compares...

Full description

Bibliographic Details
Main Authors: Joseph B Sempa, Alex Welte, Michael P Busch, Jake Hall, Dylan Hampton, Shelley N Facente, Sheila M Keating, Kara Marson, Neil Parkin, Christopher D Pilcher, Gary Murphy, Eduard Grebe, Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0220345

Internet

https://doi.org/10.1371/journal.pone.0220345

Similar Items